The following links are operated by other parties. The resources are not under the control of Project Data Sphere, and Project Data Sphere is not responsible for any of the content these resources may offer. This list and any links to the listed resources do not imply Project Data Sphere's endorsement of any third-party content, and Project Data Sphere disclaims all liability with regard to your access to and use of such content. Access to any of the content these resources may offer is at your own risk. You are responsible for complying with any legal terms that may be applicable to your access to and use of any of content offered by any of these resources.Synthetic Controls, Cytel Video
Cytel published an excellent instructional video on best practices when considering the use of synthetic controls to address accelerated treatment approvals for rare disease, considering adaptive clinical trial design, and researching the effectiveness of new treatments. Leveraging some of the published data on PDS platform, this is a great introduction to a handful of success stories. In this video, Kristian Thorlund, SVP Real World Analytics at Cytel, demonstrates a few key examples of applied use for accelerated approval (Blinatumomab 2014) and exploration of dynamic Bayesian borrowing or applying methods of different randomization methods.
Read more from the published article, Minimizing control group allocation in randomized trials using dynamic borrowing of external control data - An application to second line therapy for non-small cell lung cancer